BAUSCH + LOMB CORP (BLCO) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BLCO - CA0717051076 - Common Stock
BLCO Key Statistics, Chart & Performance
The current stock price of BLCO is 17.32 USD. In the past month the price increased by 1.35%. In the past year, price decreased by -0.23%.
BLCO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BLCO. When comparing the yearly performance of all stocks, BLCO turns out to be only a medium performer in the overall market: it outperformed 61.17% of all stocks.
BLCO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BLCO. While BLCO is still in line with the averages on profitability rating, there are concerns on its financial health.
BLCO Financial Highlights
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.43. The EPS decreased by -29.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.21% | ||
| ROE | -4.74% | ||
| Debt/Equity | 0.77 |
BLCO Forecast & Estimates
19 analysts have analysed BLCO and the average price target is 17.34 USD. This implies a price increase of 0.12% is expected in the next year compared to the current price of 17.32.
For the next year, analysts expect an EPS growth of -10.98% and a revenue growth 6.46% for BLCO
BLCO Ownership
BLCO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.78 | 16.24B | ||
| SOLV | SOLVENTUM CORP | 13.48 | 13.88B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.5 | 12.14B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 21.98 | 4.85B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.01 | 4.35B | ||
| ICUI | ICU MEDICAL INC | 18.66 | 3.67B | ||
| HAE | HAEMONETICS CORP/MASS | 15.78 | 3.54B | ||
| XRAY | DENTSPLY SIRONA INC | 7.82 | 2.46B | ||
| NEOG | NEOGEN CORP | 32.38 | 2.04B | ||
| UFPT | UFP TECHNOLOGIES INC | 30.19 | 2.01B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.09B | ||
| EMBC | EMBECTA CORP | 4.29 | 746.00M |
Related stock screener links
About BLCO
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13500
Phone: 19082552864
BAUSCH + LOMB CORP / BLCO FAQ
What does BLCO do?
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
What is the stock price of BAUSCH + LOMB CORP today?
The current stock price of BLCO is 17.32 USD. The price decreased by -0.74% in the last trading session.
What is the dividend status of BAUSCH + LOMB CORP?
BLCO does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLCO stock?
BLCO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for BLCO stock?
19 analysts have analysed BLCO and the average price target is 17.34 USD. This implies a price increase of 0.12% is expected in the next year compared to the current price of 17.32.
What is the Short Interest ratio of BAUSCH + LOMB CORP (BLCO) stock?
The outstanding short interest for BAUSCH + LOMB CORP (BLCO) is 8.17% of its float.